DK2060266T3 - Y4-selektiv receptoragonist PP2-36 til terapeutiske indgreb - Google Patents

Y4-selektiv receptoragonist PP2-36 til terapeutiske indgreb

Info

Publication number: DK2060266T3
Authority: DK; Denmark
Prior art keywords: receptor agonist; therapeutic interventions; selective receptor; selective; receptors
Prior art date: 2004-03-17

Application number

DK09075024.1T

Other languages

English (en)

Inventor

Thue Schwartz

Original Assignee

7Tm Pharma As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-03-17

Filing date

2005-03-17

Publication date

2011-11-14

2005-02-14 Priority claimed from GB0503110A external-priority patent/GB0503110D0/en

2005-03-17 Application filed by 7Tm Pharma As filed Critical 7Tm Pharma As

2011-11-14 Application granted granted Critical

2011-11-14 Publication of DK2060266T3 publication Critical patent/DK2060266T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Obesity (AREA)
Hematology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Immunology (AREA)
Biophysics (AREA)
Toxicology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Reproductive Health (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Epidemiology (AREA)
Cell Biology (AREA)
Urology & Nephrology (AREA)
Pregnancy & Childbirth (AREA)
Orthopedic Medicine & Surgery (AREA)
Child & Adolescent Psychology (AREA)
Gynecology & Obstetrics (AREA)

DK09075024.1T 2004-03-17 2005-03-17 Y4-selektiv receptoragonist PP2-36 til terapeutiske indgreb DK2060266T3 (da)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
DKPA200400436		2004-03-17
US55893204P	2004-04-01	2004-04-01
US58596404P	2004-07-06	2004-07-06
GB0503110A GB0503110D0 (da)	2005-02-14	2005-02-14
EP05716258A EP1729792B1 (en)	2004-03-17	2005-03-17	Y4 selective receptor agonist for therapeutic interventions

Publications (1)

Publication Number	Publication Date
DK2060266T3 true DK2060266T3 (da)	2011-11-14

Family

ID=43302286

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK09075024.1T DK2060266T3 (da)	2004-03-17	2005-03-17	Y4-selektiv receptoragonist PP2-36 til terapeutiske indgreb

Country Status (15)

Country	Link
US (1)	US20080269114A1 (da)
EP (3)	EP2060266B1 (da)
JP (1)	JP2007529463A (da)
AT (2)	ATE490779T1 (da)
AU (1)	AU2005224028B2 (da)
BR (1)	BRPI0508935A (da)
CA (1)	CA2560174A1 (da)
DE (1)	DE602005025199D1 (da)
DK (1)	DK2060266T3 (da)
EA (1)	EA012071B1 (da)
GB (1)	GB2427551B (da)
IL (1)	IL177681A0 (da)
MX (1)	MXPA06010345A (da)
PL (1)	PL2060266T3 (da)
WO (1)	WO2005089786A2 (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101361967A (zh) *	2004-03-17	2009-02-11	7Tm制药联合股份有限公司	用于治疗性干预的y2/y4选择性受体激动剂
GB2427550B (en) *	2004-03-17	2007-05-30	7Tm Pharma As	Y2/Y4 selective receptor agonists for therapeutic interventions
WO2006091505A2 (en) *	2005-02-24	2006-08-31	Bayer Pharmaceuticals Corporation	Neuropeptide y receptor agonists
SI1919947T1 (sl) *	2005-08-26	2013-06-28	Abbvie Inc.	Terapevtsko aktivni alfa-msh analogi
JP2009508885A (ja) *	2005-09-21	2009-03-05	７ティーエムファーマエイ／エス	治療的介入のためのｙ４選択性レセプターアゴニスト
US7851590B2 (en)	2005-09-21	2010-12-14	7Tm Pharma A/S	Y2 selective receptor agonists for therapeutic interventions
EP1990427A4 (en) *	2006-02-24	2009-04-29	Banyu Pharma Co Ltd	NPY Y4-AGONIST AS A THERAPEUTIC AGENT AGAINST A DISEASE ACHIEVED BY A MALFUNCTION OF THE DARMTRACT
US7910583B2 (en)	2007-05-04	2011-03-22	Bristol-Myers Squibb Company	[6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor agonists
JP2010526146A (ja)	2007-05-04	2010-07-29	ブリストル−マイヤーズスクイブカンパニー	［６，５］−二環式ｇｐｒ１１９ｇタンパク質結合受容体アゴニスト
US20100279930A1 (en) *	2007-07-09	2010-11-04	Stephen Robert Bloom	Human pancreatic polypeptide (hpp) analogues and their effects on feeding behaviour
US7928230B2 (en)	2007-07-17	2011-04-19	Bristol-Myers Squibb Company	Method for modulating GPR119 G protein-coupled receptor and selected compounds
MX2010011845A (es) *	2008-05-16	2010-11-22	Novo Nordisk As	Agonistas del receptor y2 y/o y4 de larga accion.
TW201006821A (en)	2008-07-16	2010-02-16	Bristol Myers Squibb Co	Pyridone and pyridazone analogues as GPR119 modulators
GB0817067D0 (en) *	2008-09-18	2008-10-22	7Tm Pharma As	Intestinal treatment
CN102438599B (zh) *	2009-03-04	2015-01-21	迈雅营养品有限公司	通过降低血糖水平来控制糖尿病的营养组合物和方法
GB201001333D0 (en)	2010-01-27	2010-03-17	Imp Innovations Ltd	Novel compounds and their effects on feeding behaviour
JP2013523822A (ja)	2010-04-08	2013-06-17	ブリストル−マイヤーズスクイブカンパニー	Ｇｐｒ１１９修飾因子としてのピリミジニルピペリジニルオキシピリジノ類似体
EP2566860B1 (en)	2010-05-06	2014-09-10	Bristol-Myers Squibb Company	Bicyclic heteroaryl compounds as gpr119 modulators
EP2566862B1 (en)	2010-05-06	2015-09-16	Bristol-Myers Squibb Company	Benzofuranyl analogues as gpr119 modulators
RU2600440C3 (ru)	2010-12-16	2021-12-10	Ново Нордиск А/С	Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
GB201101459D0 (en)	2011-01-27	2011-03-16	Imp Innovations Ltd	Novel compounds and thier effects on fedding behaviour
US10933120B2 (en)	2012-03-22	2021-03-02	Novo Nordisk A/S	Compositions of GLP-1 peptides and preparation thereof
EP2850073B1 (en)	2012-05-16	2017-07-19	Bristol-Myers Squibb Company	Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators
AU2014261336B2 (en)	2013-05-02	2019-02-28	Novo Nordisk A/S	Oral dosing of GLP-1 compounds
US9580422B2 (en)	2013-10-22	2017-02-28	Bristol-Myers Squibb Company	Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US9085637B2 (en)	2013-11-15	2015-07-21	Novo Nordisk A/S	Selective PYY compounds and uses thereof
US10583172B2 (en)	2013-11-15	2020-03-10	Novo Nordisk A/S	HPYY(1-36) having a beta-homoarginine substitution at position 35
TWI694082B (zh)	2015-06-12	2020-05-21	丹麥商諾佛儂迪克股份有限公司	選擇性ｐｙｙ化合物及其用途
CN109715637B (zh)	2016-07-22	2022-04-05	百时美施贵宝公司	葡萄糖激酶激活剂及其使用方法
BR112020014624A2 (pt)	2018-02-02	2020-12-08	Novo Nordisk A/S	Composições sólidas compreendendo agonista de glp-1, sal de ácido n-(8-(2-hidroxibenzoil) amino)caprílico e lubrificante
GB202213305D0 (en) *	2022-09-12	2022-10-26	Univ Ulster	Compositions for use in the treatment of diabetes or obesity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5349052A (en)	1988-10-20	1994-09-20	Royal Free Hospital School Of Medicine	Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5122614A (en)	1989-04-19	1992-06-16	Enzon, Inc.	Active carbonates of polyalkylene oxides for modification of polypeptides
CA2215694A1 (en)	1995-03-17	1996-09-26	Novo Nordisk A/S	Insulin derivatives
US5830434A (en) *	1997-02-26	1998-11-03	Medical University Of South Carolina Foundation For Research Development	Methods of treating non-insulin dependent diabetes mellitus with pancreatic polypeptide
EP1950224A3 (en)	1998-03-09	2008-12-17	Zealand Pharma A/S	Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
EA008829B1 (ru) *	2002-12-17	2007-08-31	Нэстек Фармасьютикал Кампани Инк.	Композиции и способы для усовершенствованной доставки пептидов, связывающихся с y-рецепторами, которую осуществляют через слизистые оболочки, и способы лечения и предотвращения ожирения
US7229966B2 (en) *	2002-12-17	2007-06-12	Nastech Pharmaceutical Company Inc.	Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
US8603969B2 (en) *	2004-02-11	2013-12-10	Amylin Pharmaceuticals, Llc	Pancreatic polypeptide family motifs and polypeptides comprising the same
GB0817067D0 (en) *	2008-09-18	2008-10-22	7Tm Pharma As	Intestinal treatment

2005
- 2005-03-17 MX MXPA06010345A patent/MXPA06010345A/es not_active Application Discontinuation
- 2005-03-17 GB GB0618824A patent/GB2427551B/en not_active Expired - Fee Related
- 2005-03-17 CA CA002560174A patent/CA2560174A1/en not_active Abandoned
- 2005-03-17 EP EP09075024A patent/EP2060266B1/en not_active Expired - Lifetime
- 2005-03-17 US US10/592,779 patent/US20080269114A1/en not_active Abandoned
- 2005-03-17 DE DE602005025199T patent/DE602005025199D1/de not_active Expired - Lifetime
- 2005-03-17 AT AT05716258T patent/ATE490779T1/de not_active IP Right Cessation
- 2005-03-17 AT AT09075024T patent/ATE519495T1/de not_active IP Right Cessation
- 2005-03-17 EP EP05716258A patent/EP1729792B1/en not_active Expired - Lifetime
- 2005-03-17 WO PCT/EP2005/002983 patent/WO2005089786A2/en not_active Ceased
- 2005-03-17 JP JP2007503303A patent/JP2007529463A/ja not_active Ceased
- 2005-03-17 PL PL09075024T patent/PL2060266T3/pl unknown
- 2005-03-17 BR BRPI0508935-2A patent/BRPI0508935A/pt not_active IP Right Cessation
- 2005-03-17 DK DK09075024.1T patent/DK2060266T3/da active
- 2005-03-17 AU AU2005224028A patent/AU2005224028B2/en not_active Ceased
- 2005-03-17 EA EA200601720A patent/EA012071B1/ru unknown
- 2005-03-17 EP EP09075040A patent/EP2057996A3/en not_active Withdrawn
2006
- 2006-08-24 IL IL177681A patent/IL177681A0/en unknown

Also Published As

Publication number	Publication date
EA012071B1 (ru)	2009-08-28
EP1729792B1 (en)	2010-12-08
BRPI0508935A (pt)	2007-09-25
MXPA06010345A (es)	2007-06-19
WO2005089786A3 (en)	2006-06-15
EP2057996A2 (en)	2009-05-13
EP2060266B1 (en)	2011-08-10
GB0618824D0 (en)	2006-11-01
EA200601720A1 (ru)	2007-04-27
JP2007529463A (ja)	2007-10-25
GB2427551B (en)	2007-05-30
EP2060266A1 (en)	2009-05-20
WO2005089786A2 (en)	2005-09-29
ATE490779T1 (de)	2010-12-15
DE602005025199D1 (en)	2011-01-20
EP2057996A3 (en)	2009-11-04
PL2060266T3 (pl)	2012-01-31
IL177681A0 (en)	2006-12-31
CA2560174A1 (en)	2005-09-29
EP1729792A2 (en)	2006-12-13
ATE519495T1 (de)	2011-08-15
GB2427551A (en)	2007-01-03
AU2005224028B2 (en)	2011-05-26
US20080269114A1 (en)	2008-10-30
AU2005224028A1 (en)	2005-09-29

Publication	Publication Date	Title
DK2060266T3 (da)	2011-11-14	Y4-selektiv receptoragonist PP2-36 til terapeutiske indgreb
DK1734971T3 (da)	2012-02-13	Indretning på polymerbasis med forsinket frigivelse
DE60317677D1 (de)	2008-01-03	Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung
DK1833799T3 (da)	2009-01-19	3-phenyl-pyrazol derivater, som modulatorer af 5-HT-2a-serotonin receptor nyttig til behandlingen af sygdomme relateret hertil
IL189948A0 (en)	2008-08-07	Y2 selective receptor agonists for therapeutic interventions
NO20083011L (no)	2008-09-19	Modulatorer av muskarine receptorer
NO20081908L (no)	2008-06-20	Selektive Y4-reseptoragonister for terapeutiske intervensjoner
NO20073482L (no)	2007-09-27	Fremgangsmåte til å stabilisere antidement medikament
ATE451364T1 (de)	2009-12-15	Als modulatoren des dopamin-d3-rezeptors geeignete azabicycloä3.1.0ühexanderivate
NO20063191L (no)	2006-10-16	Aminobenzazoler som P2Y1-reseptorinhibitorer
DK2119715T3 (da)	2012-09-10	Benzimidazolderivat og dets anvendelse som AII-receptorantagonisk
WO2008008286A3 (en)	2008-04-24	Substituted pyrazoles as ghrelin receptor antagonists
ATE490239T1 (de)	2010-12-15	Substituierte phenylpiperidinderivate als melanocortin-4-rezeptormodulatoren
DK1928850T3 (da)	2013-09-23	Midler til forebyggelse og behandling af lidelser, der involverer modulering af RyR-receptorerne
DK1729746T3 (da)	2010-03-08	Anordning til transdermal administration af nikotin
NO20084006L (no)	2008-09-26	Modulatorer av muskarinreseptorer
NO20084792L (no)	2009-01-13	Substituerte imidazol-4-karboksamider som kolecystokinin-1-reseptormodulatorer
EP2272524A3 (en)	2011-02-02	Y2 selective receptor agonists for therapeutic interventions
NO20082345L (no)	2008-05-23	Selektive VPAC2 reseptorpeptidagonister
MA28580B1 (fr)	2007-05-02	3-(4-hétéroarylcyclohexylamino) cyclopentanecarboxamides servant de modulateurs de récepteurs de chimiokines
ATE484506T1 (de)	2010-10-15	Substituierte diazepin-sulfonamide als bombesin- rezeptor-subtyp-3-modulatoren
ATE399776T1 (de)	2008-07-15	Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors
DK1789053T3 (da)	2012-08-06	Fremgangsmåde til sårheling under anvendelse af a2b-adenosinreceptor-antagonister
DE602005005298D1 (de)	2008-04-24	1-benzyl-5-piperazin-1-yl-3,4 dihydro-1h-chinazolin-2-on-derivate und die jeweiligen 1h-benzo(1,2,6)thiadiazin-2,2-dioxid und 1,4-dihydro-benzo(d)(1,3)oxazin-2-on-derivate als modulatoren des 5-hydroxytryptamin-rezeptors (5-ht) zur behandlung von erk
ATE460404T1 (de)	2010-03-15	Modulatoren von alpha7-nikotin-acetylcholin- rezeptoren und therapeutische anwendungen davon